ETH, BTC, Fiat
Token Count
1ETH =7000 OMX

Author: Daemonbounty

As per a research article published on PLOS (, scientists predict that over the next decade Genomics would be one of the largest data producing fields surpassing the likes of social media. That's seems pretty real if you note that raw data of each human genome can take up to 100 GB of space. For those who are relatively new to the word Genomics, it is the study of human genome, its analysis and application.

Genomic sequencing and analysis can have profound impact on today's healthcare sector. It can help:
  • identify individuals susceptible to specific diseases and define the remedy for those.
  • prevention of diseases in healthy individuals
  • prediction of disease risk in offspring based on the genomic analysis of parents
  • identification of specific target group for each drug
  • identification of resistant group for a specific drug or pathogen
Advancements in genomics and personalized medicine is making it increasingly affordable to do the genomic sequencing of an individual. The cost has reduced drastically from millions of dollars to just few thousand dollars over the last decade and will continue to go down. This has driven the demand for genomic sequencing and with that comes large sets of data. This leads to a few major challenges, as mentioned below, that needs to be tackled so that its full potential can be explored.

  • Informed Consent: While submitting DNA samples for sequencing, user unknowingly grants these companies lifetime access to use the genomic data. The user data can and is used without any knowledge of the user and the revenue generated also not shared with the end user.
  • Data Security and Storage: How many times you hear the news of unauthorized access of credit card, bank account, insurance and other data and feel alarmed? Think about the enormity of the situation wherein your genomic data is accessed by unauthorized or criminal personnel. The implication can be limitless. 
  • Lack of Universally Accessible Genomic Data: Most of the genomic data collected today are centrally stored and not easily accessible. There also lies single point of data loss. With advancement of Genomics, this problem will be increasingly acute and the need of decentralized and universally accessible genomic data is the need of the hour.
  • Generic Application of Genomic Data: Most of the human genomes sequenced so far are primarily used for research purpose. but these is an absolute need to shift the focus to medical diagnosis and treatment, where the physicians and pharma personnel can use the genomic data to ensure correct medication for the patient.

Project Shivom aims to solve these issues in Genomics field by creating world's largest genomic data hub and healthcare service platform based on blockchain. Blockchain will provide the much needed privacy and security of genomic data. Shivom will collect genomic data around the world (including from countries like Middle East, Asia, South America) and apply latest technology like AI and Machine Learning to provide deep insight, boost therapeutic development, molecular diagnostics of disease, risk assessment and improve the healthcare system of today.

Objectives of Project Shivom:

  • Shivom will make genomic sequencing much more affordable and accessible by providing subsidized genomic testing to people from all parts of the world. It will help democratizing the genomic data. It will have partnership with local Governments and labs around the world that will provide users with last mile access to genomic test facilities. 
  • Create a healthcare marketplace for the genomic data where the users can monetize the genomic data.
  • Provide a platform where services like health app, nutrition advice services, lifestyle management can be built on top of the genomic data.
  • Foster a partnership with healthcare providers wherein the physicians and pharma personnel can make use of genomic data to prescribe appropriate medication.
  • Shivom will onboard genetic counselors around the globe wherein people can access their help via telemedicine services.
  • Last but not the least, Shivom will provide researchers around the world access to decentralized genomic data to perform clinical trial and research.

OMX Token Sale:

OMX is an ERC20 compatible token that will fuel Shivom platform. All the transactions, between individuals, pharma companies, research organizations, insurance companies, done on the platform will be based on OMX tokens.
Symbol                                         OMX
PlatformERC20 (Ethereum)
Total Tokens3,000,000,000
Available for Sale990,000,000
Price1 ETH = 7,000 OMX
AcceptingETH, BTC, FIAT
SoftCap15,000 ET
PreSale Dates16-Apr-2018 to 27-Apr-2018
CrowdSale03-May-2018 to 10-May-2018

Token Distribution:

Growth Pool20%

Utilization of Fund:

Research and Platform Development32%                                                        
Data Storage6%
Laboratories 25%




Axel has over 20 years of Research and Development leadership experience in genomics, epigenetics, biomarker discovery, Bio-IT, aging & longevity. He is the Author of the ‘Blockchain & Healthcare Strategy Guide’, the standard compendium for the healthcare industry. Axel translates scientific discoveries into practical applications to help understand, diagnose & treat complex disorders, but also to promote cutting-edge technologies that could transform precision medicine and the way we age. Axel is also a Member of the Blockchain Research Institute in Toronto. He holds a Ph.D. in Human Genetics from the University of Cologne.



With a background in investment banking and wealth management, Gourish is an accomplished business leader, angel investor and social entrepreneur with a focus on performance, growth, and innovation. He drove 30m$+ revenue in his last venture into a highly competitive marketplace and has founded three successful companies in the digital health space. Through Project Shivom, Gourish combines his deep interest in this sector alongside advocacy for blockchain and distributed ledger technology that can make a transformational difference both for business and for wider society.



Sally combines a depth of experience as a Chief Technology Officer, Practising Professor of FinTech and Global Strategic Advisor, consulting on the application of disruptive technologies for both business and societal benefits. She is an award-winning thought leader in innovation, digital transformation and emergent technology, notably blockchain, artificial intelligence, machine learning, and robotics. A member of the Forbes Technology Council, Sally is an accomplished author with regular contributions to leading business, technology, and academic publications. She is an international keynote speaker and respected online influencer across multiple social media channels and consistently rated in the top 10 for blockchain and social media influence worldwide.



A kick-ass business development expert, Per is a leader in Social Media Management Solutions and he knows how to engage social marketing in any organization. Worked with Carlsberg, IKEA, WPP (and associated agencies) and many other global brands. A specialist in sales on the highest possible levels to enterprise customers. He wants to change the world through Experience Management, which is interconnecting companies with their stakeholders to continually improve their brand quality and customer experiences.



Akash is a blockchain entrepreneur. He founded India’s first blockchain company, Auxesis Group during his undergraduate studies at IIT Bombay. Auxesis today is counted among The Top 100 Most Influential Blockchain Company in the World. Akash also founded Blockchain Lab, India and is on the advisory board of hot Blockchain startup Cashaa, a zero fee money remittance company . He also sits on an advisory board to Entrepreneurship Club of MISB Bocconi. Before founding Auxesis, Akash was the manager of The Entrepreneurship Cell, IIT Bombay which is India’s largest entrepreneurship promoting club. As a manager, he led a team of 120 volunteers to organize global level entrepreneurship programs and summits. He was also a core group member of Innovation Cell, IIT Bombay where the team successfully proposed a new model for India’s first self-driving car.


White Paper

Investment Info
Accepting ETH, BTC, Fiat
Token Info
Token OMX
Platform Ethereum
Type ERC20
Token Price 1ETH =7000 OMX
Token Count 3,000,000,000
Crowd Sale Start Date 2018-April-16
Crowd Sale End Date 2018-May-16

Write a review

Note: HTML is not translated!
    Bad           Good

Author: Daemonbounty

Disclaimer : Please note that we are not associated with the ICO nor are paid for preparing this review. This is our personal opinion and contributors are advised to do their due diligence before contributing to the ICO.

Project Shivom is a very ambitious project that can change the healthcare landscape across the globe. Healthcare sector has maximum impact on our society, yet it is one of the sector that is least affected by technological advancements in other fields. Telemedicine, machine learning, artificial intelligence, data privacy etc. are still new for healthcare sector. Project Shivom aims to combine all these aspects with human genomics to help solve some of the major challenges in today's healthcare sector. Does it have the potential to do so? Do they have the qualified team for that? Do they have a community that will support their roadmap? We have analyzed all those aspects and tried to rate the ICO. Being an ICO in healthcare sector, it definitely have a social impact but during the analysis we tried to be more objective and weighed both on social and financial aspects of the ICO.

We have analysed the ICO based on the below parameters: 

1. Necessity or problem statement (12%)

2. White paper (9%)

3. Product Status (10%)

4. Team (10%)

5. ICO Pricing (7%)

6. Business Model/Revenue Source (15%)

7. Token Value Increment Options (15%)

8. Social Media Presence/Hype (10%)

9. Competitors (12%)

Below is the score we have given for each parameter and overall rating of the ICO.

Parameter Total  Score
Necessity or problem statement
White Paper
Product Status
ICO Pricing
Business Model/Revenue Source
Token Value Increment Options
Social Media Presence/Hype
100 87.70

Please continue reading for detailed analysis. 

1. Necessity or Problem Statement (12%)

Even though genomic sequencing is becoming popular with each passing day, there are many issues that needs to be addressed for the system to be effective for all the stake holders. There are issues related to data security and privacy. Individual's genomic data is used by third parties without explicit consent of the person. Also many a times we hear the news about data theft that pose a great risk to the society. The revenue generated from the genomic data is not at all shared with the individuals and as most of the current genomic data are stored in silos i.e. in the centralized databases of the corporations that collect DNA samples for sequencing, it becomes a bottleneck for research and development and become single point of failure. Researchers around the world don't get access to these genomic data in a timely manner which delays and complicates the clinical trial and research. Project Shivom aims to solve these by creating a genomic data hub and healthcare service platform based on blockchain. There is an acute necessity of these kind of innovation in healthcare sector and we really appreciate the novelty of the concept. We give them 9 out of 10 i this regard.

2. White paper (9%)

You can go through their whitepaper in the ‘Details’ tab.

Averagely written whitepaper. The whitepaper has all the required details including the project vision, market overview, problem statement, solution, business model and technical architecture. However, when you go through it, you will feel like there is a lack of coherence in the manner in was written. Seems like each section was written by a different person without any synergy with others. As some sentences it sounded like it was going all over the places. However, it gives a much needed details about the market condition of human genomics and the corresponding problems it faces today. The technical architecture section is well defined and we liked it. Overall we give 6 out of 10.

3. Product Status (10%)

They have a link to POC page on their website. We expected to see some details about the product. However, it has just a mock up displayed (with lorem ipsum written on it) as shown below.

We are not trying to take anything from the project but these things go a long way in adding credibility to the project. We would have really loved to check a basic POC or alpha of the product before ICO but that's how it is for most of the ICOs at the moment. We give then 5 out of 10 for this.

4. Team (10%)

They have managed to build up one of the most amazing team that we have seen till date. The CEO Axel, COO Gourish, Sally, Henry and others form an impeccable team. Their CTO Akash is one of the most notable names in India and founded the renowned Auxesis group, Indian's first blockchain company. He is also heading blockchain foundation of India and have great relationship with Indian Govt. and business fraternity. These aspects will add a lot of value for Shivom in future as it tries to build partnership with Indian Govt. Just fyi, they have already signed a MoU with Govt. of Andhra Pradesh and Akash has a big hand behind that. Overall a highly capable team who has all the talent and resources to pull off an ambitious project like this. We give them 9 out of 10 for this.

5. ICO Pricing (7%)

They are planning to sell 33% of total available 3,000,000,000 tokens to raise $33,000,000. This makes the project valued at $100,000,000. Sounds expensive? Well not really. If you understand the reach and impact of the project, they in fact may need much more than that to execute the roadmap items. They have 20% of tokens available in reserve and another 20% in growth pool which will come handy in future. However, we really didn't appreciate the fact that 24% of tokens goes to founders and advisers. That's a huge portion of tokens and it is not a good point for a project that has a huge social value associated with it. We give them 8 out of 10 for pricing.

6. Business Model/Revenue Source (15%)

The major business model for Shivom will be from data storage and sharing of human genome. As they are going to build one of the largest decentralized genome bank, it will be in huge demand in future and make a case for continuous future revenue. Apart from that they will have a peripheral healthcare marketplace around all those genomic data and this will give then second stream of revenue source. In addition, pharma companies will be able to use these data in two forms. One, to use for clinical research and would not mind paying for the same. Second, they will be able to use these user information for selective advertisement of drugs and solution to patients. Even insurance companies can utilize these data for advertising purpose. So advertising will be one of the major source of revenue in future. Overall, multiple revenue source and the best part is most of them are major revenue sources unlike other projects where the secondary revenue streams are minimal in nature. We give them 9 out of 10 in this aspect.

7. Token Value Increment Options (15%)

There are multiple use cases for OMX tokens that will help maintain and increase its valuation over time.

IndividualsPay using OMX tokens for services like genome sequencing, doctor counselling, other healthcare services
DoctorsPay for accessing user genomic data that will help them provide better medication
Healthcare SystemsFinancing of various programs
Research InstitutionsPay using OMX tokens to access genomic data for clinical trials
PharmaciesUse genomic data to sale proper medication to patients
Pharma companiesPay using OMX tokens for data and advertisements
Insurance CompaniesPay commission for selling custom insurance solutions to individuals based on their genomic data

As mentioned in the above list, there are ample use cases for OMX token in the ecosystem. With increased popularity of the platform, the value of OMX token is bound to increase.However, till the point, OMX token is not universally accepted, the platform must support fiat currency and that may impact the value of OMX token. We give them 8 out of 10 in this aspect. 

8. Social Media Presence/Hype (10%)

Their evangelizing efforts in various social media platforms like Telegram, Facebook, Twitter, LinkedIn, are all intensive and is gathering the intended mindshare among ICO enthusiasts. 

Twitter – 40000+ followers

Facebook – 4000+ followers

Telegram – 45000+ followers

They are spending a lot of effort on marketing and that has given them huge attention. We give them 9 out of 10 in this aspect. 

9. Competitors (12%)

There are many regional players in the space which are currently active in different regions. It will be very difficult for Shivom to compete and make a mark in the initial days. Also other players, based on blockchain, like Etheal, Patientry, Medicalchain and Well will determine the level of competition that Shivom will face. However, if they provide a decent service with ubiquitous platform then they will be able to  easily penetrate the market and achieve their desired target.

Based on their roadmap and capable team, we hope that they will be able to fend of their competitor and capture market share. We give them 7 out of 10 in this aspect.

Based on our analysis we give a overall score of 87.7 out of 100 to Shivom which is an outstanding rating.

The Shivom has an interesting and novel ideathat aims to transform the Genomics field in specific and healthcare sector in general. healthcare is one of the most revenue generating sectors in the owrld and yet it is the most neglected with respect to penetration of technological innovations. Shivom aims to bridge that gap and if succeeds, it will have a huge potential to be the market leader in this segment. We also like the business model and gowth prospect of the project and having a capable team helps. We see both short term and long term demand for the OMX tokens and thus expect project supporters to benefit from it. 

We give it “Outstanding” rating and a long term investment option with low risk.